TOP TEN perturbations for NM_000405 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000405
Selected probe(set): 212737_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000405 (212737_at) across 5339 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):3.3173532
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

doxorubicin study 3 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):3.310852
Number of Samples:2 / 2
Experimental doxorubicin study 3
MCF7 cells treated with 2uM doxorubicin for 24 hours. ATC code:
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):3.0802965
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):-2.8741426
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 ?C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 ?C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 ?C in 6-well plates.

Sjogren's syndrome study 1 (advanced) / normal minor salivary gland tissue

Relative Expression (log2-ratio):2.7234373
Number of Samples:2 / 4
Experimental Sjogren's syndrome study 1 (advanced)
Whole minor salivary gland samples of patients with advanced Sjogren's syndrome.
Control normal minor salivary gland tissue
Whole minor salivary gland samples from non-Sjogren's syndrome control subjects.

Barrett's esophagus study 3 / normal esophageal epithelium sample

Relative Expression (log2-ratio):-2.5174332
Number of Samples:17 / 18
Experimental Barrett's esophagus study 3
Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection.
Control normal esophageal epithelium sample
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy.

gefitinib study 2 / wild type A431 cell sample

Relative Expression (log2-ratio):-2.3971682
Number of Samples:3 / 3
Experimental gefitinib study 2
Gefitinib-resistant A431 (A431 GR) cells generated by growing parental cells in the presence of increasing concentrations of gefitinib up to 3 ?M. Cells were selected and maintained in gefitinib (3?M). ATC code:
Control wild type A431 cell sample
A431 wild type cells.

IL-4; GM-CSF study 1 (late) / untreated monocyte sample

Relative Expression (log2-ratio):2.3627262
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (late)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

oligodendrocyte progenitor cell study 2 (O4-;CD140a+) / oligodendrocyte progenitor cell study 2 (O4-;CD140a-)

Relative Expression (log2-ratio):2.2854967
Number of Samples:5 / 5
Experimental oligodendrocyte progenitor cell study 2 (O4-;CD140a+)
Fetal oligodendrocyte cells between 20-22wk gestational age derived from fetal brains were FACS sorted on the basis of CD140a (PDGFRA) antigens. Samples were O4-/CD140a+.
Control oligodendrocyte progenitor cell study 2 (O4-;CD140a-)
Fetal oligodendrocyte cells between 20-22wk gestational age derived from fetal brains were FACS sorted on the basis of CD140a (PDGFRA) antigens. Samples were O4-/CD140a-.

PI3Kg inhibitor; GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):-2.2419147
Number of Samples:10 / 10
Experimental PI3Kg inhibitor; GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with gamma phosphoinositide 3-kinase (PI3Kg) inhibitor and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.